EP Vantage 2013 Pharma & Biotech, and MedTech Reviews
| EP Vantage Pharma and Biotech 2013 in Review
The latest report by EP Vantage identifies the key trends that defined the pharmaceutical and biotech industry in 2013.
The cautious optimism of 2012 turned into a fully fledged biotech boom in 2013, marked by surging company valuations in the US and the opening of the IPO floodgates. The pharma and biotech sector also saw an increase in M&A deal values, buoyant licensing activity and sustained venture capital investment last year.